CHICAGO -- The bispecific T-cell engager tarlatamab (Imdelltra) significantly prolonged survival in the second-line treatment ...

Patients with oligometastatic lung cancer may live longer with surgery, but experts stress the need for multidisciplinary ...

Study examines treatment options for those with operable non-small cell lung cancer, the leading cause of cancer deaths ...

Adding immunotherapy to chemotherapy before surgery for patients with operable non-small cell lung cancer (NSCLC) - the ...

Late-stage trials showed that Tecentriq combined with lurbinectedin led to a 46% reduction in the risk of the disease ...

Patients with stage II and IIIB non-small cell lung cancer (NSCLC) with an EGFR mutation had better outcomes when treated ...

Amgen has detailed a positive phase 3 readout for its T-cell engager Imdelltra in previously treated small cell lung cancer ...

Prof Patrick Forde of the Trinity St James’s Cancer Institute presented the findings at the latest meeting of the American ...

A 14-gene molecular assay could help predict which patients with early-stage non-small cell lung cancer will benefit from ...